Key result
The T vector velocity biomarker Tr40c separated pure potassium channel blocking drugs from multichannel blocking drugs with an AUC of 0.90 (95% CI 0.88-0.92), outperforming J-T peak c.
Why the study?
Does the T vector velocity (TVV) based biomarker improve the assessment of drug effects on cardiac ventricular repolarization compared to J-Tpeakc and QTcF?
Observational
Does the T vector velocity (TVV) based biomarker improve the assessment of drug effects on cardiac ventricular repolarization compared to J-Tpeakc and QTcF?
Effect estimate: AUC 0.90 (95% CI 0.88 to 0.92)
T vector velocity (TVV) based biomarkers improve the assessment of drug-induced proarrhythmic risk by better differentiating pure potassium channel block from multichannel block compared to traditional ECG parameters.
Authors
No takes yet. Share an insight, caveat, or question.
Tr40c may refine ECG differentiation of drug repolarization effects; leaves open clinical translation to proarrhythmic risk assessment.
Bystricky et al. (2018) conducted an observational in Drug effects on cardiac ventricular repolarization. T vector velocity (TVV) biomarkers (Tr40c) vs. J-T peak c was evaluated on Separating pure potassium channel blocking drugs from multichannel blocking drugs (AUC 0.90, 95% CI 0.88 to 0.92). The T vector velocity biomarker Tr40c separated pure potassium channel blocking drugs from multichannel blocking drugs with an AUC of 0.90 (95% CI 0.88-0.92), outperforming J-T peak c.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: